Amit Mehta, MD

Dr. Amit Mehta, a medical oncologist and urothelial carcinoma expert, shares insights on the latest advancements in bladder cancer treatment. He highlights the transformative FDA approval of enfortumab vedotin combined with pembrolizumab. Discussion includes how treatment strategies differ for patients with lymph node–only versus distant metastases, and the growing significance of biomarkers like Nectin‑4. Mehta emphasizes patient education, early detection of side effects, and the importance of a multidisciplinary approach in managing complications.